Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Cumulative association of five genetic variants with prostate cancer.

Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO, Hsu FC, Zhu Y, Bälter K, Kader AK, Turner AR, Liu W, Bleecker ER, Meyers DA, Duggan D, Carpten JD, Chang BL, Isaacs WB, Xu J, Grönberg H.

N Engl J Med. 2008 Feb 28;358(9):910-9. doi: 10.1056/NEJMoa075819. Epub 2008 Jan 16.

2.

A systematic review of replication studies of prostate cancer susceptibility genetic variants in high-risk men originally identified from genome-wide association studies.

Ishak MB, Giri VN.

Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1599-610. doi: 10.1158/1055-9965.EPI-11-0312. Epub 2011 Jun 29. Review.

3.

Prostate cancer genomics, biology, and risk assessment through genome-wide association studies.

Nakagawa H, Akamatsu S, Takata R, Takahashi A, Kubo M, Nakamura Y.

Cancer Sci. 2012 Apr;103(4):607-13. doi: 10.1111/j.1349-7006.2011.02193.x. Epub 2012 Jan 29. Review.

4.

[Clinical and basic aspects of familial prostate cancer].

Suzuki K, Matsui H, Ohtake N.

Gan To Kagaku Ryoho. 2013 Feb;40(2):159-63. Review. Japanese.

PMID:
23411953
5.

Genetics of prostate cancer risk.

Pomerantz MM, Freedman ML.

Mt Sinai J Med. 2010 Nov-Dec;77(6):643-54. doi: 10.1002/msj.20222. Review.

PMID:
21105126
6.

[Genetic polymorphisms of susceptible genes associated with prostate cancer].

Liu Y, Xu Y.

Zhonghua Nan Ke Xue. 2010 Jul;16(7):651-5. Review. Chinese.

PMID:
20873603
7.

Single nucleotide polymorphisms in DNA repair genes and prostate cancer risk.

Park JY, Huang Y, Sellers TA.

Methods Mol Biol. 2009;471:361-85. doi: 10.1007/978-1-59745-416-2_18. Review.

8.

Genetic predisposition to prostate cancer: Update and future perspectives.

Demichelis F, Stanford JL.

Urol Oncol. 2015 Feb;33(2):75-84. doi: 10.1016/j.urolonc.2014.04.021. Epub 2014 Jul 2. Review.

PMID:
24996773
9.

A genetic-based approach to personalized prostate cancer screening and treatment.

Helfand BT, Catalona WJ, Xu J.

Curr Opin Urol. 2015 Jan;25(1):53-8. doi: 10.1097/MOU.0000000000000130. Review.

10.

Clinical validity and utility of genetic risk scores in prostate cancer.

Helfand BT, Kearns J, Conran C, Xu J.

Asian J Androl. 2016 Jul-Aug;18(4):509-14. doi: 10.4103/1008-682X.182981. Review.

11.

When is a genetic test suitable for prime time? Predicting the risk of prostate cancer as a case-example.

Li-Wan-Po A, Farndon P, Cooley C, Lithgow J.

Public Health Genomics. 2010;13(1):55-62. doi: 10.1159/000218710. Epub 2009 May 13. Review.

12.

[Single nucleotide polymorphisms and prostate cancer].

Ma C, Liu CX, Huang P.

Zhonghua Nan Ke Xue. 2014 Aug;20(8):738-42. Review. Chinese.

PMID:
25195373
13.

A comparison of genetic risk score with family history for estimating prostate cancer risk.

Helfand BT.

Asian J Androl. 2016 Jul-Aug;18(4):515-9. doi: 10.4103/1008-682X.177122. Review.

14.

The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making.

Van den Broeck T, Joniau S, Clinckemalie L, Helsen C, Prekovic S, Spans L, Tosco L, Van Poppel H, Claessens F.

Biomed Res Int. 2014;2014:627510. doi: 10.1155/2014/627510. Epub 2014 Feb 19. Review.

Supplemental Content

Support Center